Marcaine Spinal 0,5 % Heavy

Bupivacaine, the active ingredient in Marcaine Spinal 0.5% Heavy, is a local anesthetic (amide) presented as a 0.5% (5 mg/mL) spinal injection solution for intrathecal use. It provides surgical anesthesia, labor analgesia and cesarean section anesthesia.

GNH USA supplies Marcaine Spinal 0.5% Heavy as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Bupivacaine is used as a local anesthetic for procedures requiring spinal blockade.

- Surgical anesthesia: provides dense sensory and motor block for operative procedures. - Labor analgesia: offers effective pain relief during vaginal delivery. - Cesarean section anesthesia: enables safe anesthesia for elective or emergency C‑section.

Bupivacaine administered intrathecally can be associated with a range of adverse reactions.

Common Side Effects: - Hypotension: transient drop in blood pressure due to sympathetic blockade. - Bradycardia: slowed heart rate occasionally observed. - Nausea: mild to moderate nausea during onset. - Pruritus: itching, often at the injection site.

Serious or Rare Side Effects: - High spinal block: extensive anesthesia leading to respiratory compromise. - Cardiac arrhythmia: abnormal heart rhythms, potentially severe. - Neurotoxicity: persistent neurologic deficits or spinal cord injury.

When using Marcaine Spinal 0.5% Heavy, clinicians should observe several safety considerations.

- Patient assessment: evaluate cardiovascular status and contraindications before administration. - Dose titration: use the minimum effective volume to achieve desired block. - Monitoring: continuously monitor blood pressure, heart rate and respiratory function. - Allergic reaction: be alert for signs of hypersensitivity such as rash or bronchospasm. - Pregnancy: consider risk‑benefit; category C, use only if benefits outweigh potential fetal risk. - Store at ambient temperature: keep below 25 °C, protect from light and moisture in original container.

Bupivacaine may interact with other agents that affect cardiac conduction or central nervous system function.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): can potentiate cardiotoxicity. - Beta‑blockers: may exacerbate bradycardia and hypotension. - General anesthetics (e.g., propofol, volatile agents): increase risk of profound spinal block.

Moderate Interactions (Monitor Closely): - Opioids administered epidurally: additive respiratory depression. - Calcium channel blockers: may enhance hypotensive effect. - MAO inhibitors: potential for prolonged nerve block.